{"ticker": {"uuid": "9c48abdf-778c-4731-bf8f-1624b2412f74", "symbol": "FBRX", "name": "Forte Biosciences Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Forte Biosciences stock hits 52-week high at $45.39", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOYURjY3NCbGx3RzhJTG1nUFJOcFM2aFk3dHgzZ2N1bzZmLWVrYUduOXdFbFZNY3d4eVhJUUNlcDJBLWoxZFdjYzdsbjFjbHVBN01pZzVMQ2lFZjRnX3dTaE9tSldnZkRGQngwcERYWHJmQm5MMUNiZHlwZ2xpcDFPeUlfMjlPaTVvOGtwWW12TXgxS0dmeGF5Z3pZS2VOYTQ4T0Y3WVVmRWs?oc=5", "source_name": "Investing.com", "published_at": "2026-07-15T14:19:45+00:00", "published_display": "15 Jul 2026 14:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences stock hits 52-week high at $45.39 By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPT3R4RW90VUF0QS1UMkxmTzR6eUlQRmFveE5wZ29JX3VpdUtSdnNqS0VERnpuNmtSZC1pa2ZlejhtVTItYl9sLU9QR3hhNFVQYzZGT0pJa1B4RTFZTi1oOTI3aUN4YkVOSGZweUdPZHgyMlhSYmlkY1JETWpGWHhIX0pxTEFFQWVTTFpmMUhiMG9WckJ0TVlXNUxXc1ZDU0FkREN5UjJrWHctYjFZVGc?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-15T14:18:46+00:00", "published_display": "15 Jul 2026 14:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FEDERATED HERMES, INC. Acquires Additional Shares in Forte Biosciences Inc", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOQnZTdXhtbU1ENkcyQjNYcUxiLU5XSmpOLUV2ZExjbUs0OVdyX0haNFpNS1o2S2xXeHNSYVFtWmZld1NpdnFTOVU0TVNaQnFRNncxUmdjVWxhNHBLYi1jdVA2OWp1aUgtRWs2dW9TaTBUSXF3emdSVEZoQTZrNU1DUlN0VlhyMV9KWUx3M28xQlg4aG1nLW5IaTd0M2o5U2hfUHk0cEVFNHNvN1E2d29QdQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-15T01:05:22+00:00", "published_display": "15 Jul 2026 01:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences, Inc. (FBRX) Discusses Positive Results From FB102 Phase 1b Vitiligo Study and Mechanism of Action - Slideshow (NASDAQ:FBRX) 2026-07-13", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxOSGZ6S2lRMU85NzE4RFVqM3RoYVNQR0toZTU2QkVETHZBVmFPZ0I2RFpBWGFiYi16cWRnSVUzbWFOcTlKbGNuTy1NVVF4WTN6RTEzTG9TWmc2NzdlRVhfTHd1SUtzUnRjWF9LVFppenl4eDVNT052WV96ekVvcDl5ZzNuYTZiNThiVkgzNWF4NmZSeWhhckgtTnJCNGpfMmpTR3RwYXFCWDFhMXhFQkJoY3BtS0FWTFpqSkdRZzNGbWRudVF5dmxaUnhxVE1fdw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-13T23:06:40+00:00", "published_display": "13 Jul 2026 23:06", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Forte Biosciences, Inc. \u2013 NASDAQ:FBRX", "summary": "The article focuses on the \"Price to book forward\" financial metric for Forte Biosciences, Inc. (NASDAQ: FBRX). It is presented as part of TradingView's financial data offerings for the biotechnology company. The content appears to be a stub or a section within a larger financial", "url": "https://www.tradingview.com/symbols/NASDAQ-FBRX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T20:13:40", "published_display": "13 Jul 2026 20:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxQaFBiT0hkUnd5SGMwZXNLMF83TmU4aFlYOHRsWUd6RWQ4eWJLSjQ2TURfYTNYVWF1R01hajN4T0tKSUg1bVRPSW43NXdQX0Z3SXRVSGlqODlwTlRqcGZtMlVEeUcwLTVoRmJfQmxJdERoOXdxVFJreWp3dmN4djhmLTJUYzdPRWxWem9zeTFxWWZVd0hMdmhCdkkzQjJ0QTU5RFkybUdKQ2EtUHROQzFJYlFWa3NGZkVtX1NZMDQ3bjVkdkpZTGZfNzFSZk5UZGxYNmFncHpXMGlYZ2x0RkI1di1lUmZjcGhIZ3NGbEVZTVBuMzZTdFlQLVhkMTdCZGpocjItRE5nYmQ3V1BLdnVtQ2cwbjJfd19aMl9aM0F2eDltTVRqczBabm1Sbk1hTy1RTk9OYjI3NlpLenRLLWYxVXlGT0JGZHRES2xCaEkwTml2Zw?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T14:44:45+00:00", "published_display": "13 Jul 2026 14:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to revenue forward of Forte Biosciences Inc. \u2013 FWB:37T", "summary": "This article provides the enterprise value to revenue forward for Forte Biosciences Inc., traded on the Frankfurt Stock Exchange under the symbol FWB:37T. It highlights the financial data available for the company, indicating the market is currently closed with no trades. The con", "url": "https://www.tradingview.com/symbols/FWB-37T/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T10:10:39", "published_display": "13 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FBRX Stock Soars As FB102 Vitiligo Data Ignite Biotech Momentum", "summary": "Forte Biosciences Inc. (FBRX) stock surged by 13.65% after announcing positive Phase 1b clinical trial data for its FB102 vitiligo treatment, showing significant facial vitiligo improvements, durable off-drug benefits, and a clean safety profile. This strong data has increased in", "url": "https://stockstotrade.com/news/forte-biosciences-inc-fbrx-news-2026_07_10/", "source_name": "StocksToTrade", "published_at": "2026-07-10T16:20:54", "published_display": "10 Jul 2026 16:20", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences' Vitiligo Triumph: A High-Stakes Bet on Broad Autoimmune Potential", "summary": "Forte Biosciences' stock surged after positive Phase 1b clinical trial results for its drug candidate, FB102, in vitiligo patients. The study showed statistically significant improvements in vitiligo symptoms with a favorable safety profile and sustained efficacy post-treatment. ", "url": "https://www.kavout.com/market-lens/forte-biosciences-vitiligo-triumph-a-high-stakes-bet-on-broad-autoimmune-potential", "source_name": "Kavout | AI", "published_at": "2026-07-10T16:09:48", "published_display": "10 Jul 2026 16:09", "sentiment": "positive", "sentiment_pct": 85, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data", "summary": "Forte Biosciences (FBRX) shares surged 78.3% following positive top-line results from a phase Ib study of FB102 for vitiligo. The study showed statistically significant improvements in facial depigmentation and a favorable safety profile for FB102, boosting investor confidence. T", "url": "https://www.tradingview.com/news/zacks:9ae15f344094b:0-fbrx-stock-rallies-78-on-positive-early-stage-vitiligo-study-data/", "source_name": "TradingView", "published_at": "2026-07-10T15:39:57", "published_display": "10 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 85, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences Skin Pigmentation Disorder Drug Shows Strong Efficacy, Safety In Early Study", "summary": "Forte Biosciences' FB102 drug showed significant efficacy and a favorable safety profile in an early-stage study for vitiligo, a skin pigmentation disorder. The Phase 1b trial demonstrated statistically significant improvements in facial repigmentation, with benefits continuing e", "url": "https://www.sahmcapital.com/news/content/forte-biosciences-skin-pigmentation-disorder-drug-shows-strong-efficacy-safety-in-early-study-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T15:09:48", "published_display": "10 Jul 2026 15:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences' FB102 Hits Key Goal in Vitiligo Study, Shows Durable Improvement", "summary": "Forte Biosciences announced that its drug FB102 met its primary endpoint in a small, placebo-controlled vitiligo study, demonstrating a statistically significant and durable improvement in facial Vitiligo Area Scoring Index. The study showed continued improvement in patients even", "url": "https://finance.yahoo.com/healthcare/articles/forte-biosciences-fb102-hits-key-140238343.html", "source_name": "Market source", "published_at": "2026-07-10T14:09:24", "published_display": "10 Jul 2026 14:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences: FB102 Is Becoming A Platform Story, Not A Single-Indication Bet (NASDAQ:FBRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPek5fdVdDZ2pTWm9RTHpOS3dXcnR3bzJpeHMwNlAyRUd4OGVqQ2JGaEVSREhDYnhWTDdhcW54QU9TTjE3aE5aVUxhc3IzeUxQRGVya3p3bVhyejUyeHJ5VGFjQ1pFMnFZd2hPSmFqMTQ2OTI1QXlMNTJxVHFuQ3dmdWpJb3hxQ2RHRlFPNk05RldVSlA0UG9jOWQ3QXZySTZydTFiZUhXYkttV3o3dFAzbTZQZnJSU3FGQzVNQXhR?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-10T12:25:00+00:00", "published_display": "10 Jul 2026 12:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$Forte Biosciences (FBRX.US)$ Why $FBRX surged today", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNXzNkLWpQX1g4WU1wTE9FQ1JwNFduSnAwVlUtOFhVWS1FWUpOUUNQR3JxTEE2dGo2MkdmNjE3VUNRaE4tcUpPQjNRZGNiVGJ2NnlTaGJRVGVPNU1fcU84UG41WkphaEU5dzZfV21xTUVYWUFwakkwSmdFR0o0bERwOVhxUTFFdkRidnRfU2ZwbHI3UndfS0F2TXBYMjc4WDVtUTVuVS1BWmpkbE9KcXlhTWVB?oc=5", "source_name": "Moomoo", "published_at": "2026-07-10T02:48:22+00:00", "published_display": "10 Jul 2026 02:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Bio surges on early-stage trial data for vitiligo therapy", "summary": "Forte Biosciences' stock surged after the company released early-stage trial data for its lead asset, FB102, a vitiligo therapy. The results showed a statistically significant improvement in vitiligo symptoms as early as nine weeks, leading to a positive market reaction for FBRX.", "url": "https://seekingalpha.com/news/4612692-forte-bio-surges-trial-data-vitiligo-drug", "source_name": "Seeking Alpha", "published_at": "2026-07-10T03:11:25", "published_display": "10 Jul 2026 03:11", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences shares surge after positive phase 1b vitiligo results", "summary": "", "url": "https://finance.yahoo.com/m/6ff17908-f387-3589-adf4-3cc866f6d614/forte-biosciences-shares.html", "source_name": "Proactive", "published_at": "2026-07-09T17:26:00+00:00", "published_display": "09 Jul 2026 17:26", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences Reports Positive Phase 1b Vitiligo Results", "summary": "Forte Biosciences reported positive results from its Phase 1b trial of FB102 for vitiligo, showing a significant mean improvement in facial vitiligo and a favorable safety profile. These findings support the potential of FB102 and the company's broader autoimmune pipeline, includ", "url": "https://www.tipranks.com/news/company-announcements/forte-biosciences-reports-positive-phase-1b-vitiligo-results", "source_name": "TipRanks", "published_at": "2026-07-09T14:41:15", "published_display": "09 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences reports positive Phase 1b vitiligo data for FB102 with 29.6% mean FVASI improvement", "summary": "Forte Biosciences", "url": "https://www.tradingview.com/news/tradingview:79e94f7b74bb8:0-forte-biosciences-reports-positive-phase-1b-vitiligo-data-for-fb102-with-29-6-mean-fvasi-improvement/", "source_name": "TradingView", "published_at": "2026-07-09T14:41:15", "published_display": "09 Jul 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences Shares Climb After Positive Phase 1b Vitiligo Trial Results (FBRX)", "summary": "Forte Biosciences (NASDAQ:FBRX) shares rose 12% following positive results from its Phase 1b trial of FB102 for vitiligo. The study demonstrated statistically significant improvements in facial repigmentation, particularly in patients with more extensive disease, and showcased a ", "url": "https://finance.yahoo.com/healthcare/articles/forte-biosciences-shares-climb-positive-140925067.html", "source_name": "Market source", "published_at": "2026-07-09T14:09:47", "published_display": "09 Jul 2026 14:09", "sentiment": "positive", "sentiment_pct": 94, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enovix, Forte Biosciences rally premarket; PepsiCo slips", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNTGhlU0FPQXN5NHl3NTBRSkFwMElRcEdvZy1CSi1HT3dkMTNXdTY4SUFHcUxGOXprcGpuSHBMa01oQWtfbC1RbFZwc0ZhMU1lNFl6bWRhaXNjR25waWI1Ykc0UmdfeFNMYWxWRnl1ckF0NlN3eF8wNklTTk14UWI3SUtNUndwckpHSnZ0YWEtMG1HZU92NzNnLVFaWWgxQUtwLXA1MGlBUVRUem5yU1pSOQ?oc=5", "source_name": "Investing.com", "published_at": "2026-07-09T12:34:05+00:00", "published_display": "09 Jul 2026 12:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences stock jumps on positive vitiligo trial data", "summary": "Forte Biosciences (NASDAQ:FBRX) shares surged 12% after announcing positive results from its phase 1b study of FB102 for vitiligo. The treatment showed statistically significant improvement in FVASI from baseline, with 29.6% for FB102 compared to 7.9% for placebo, and even greate", "url": "https://www.investing.com/news/stock-market-news/forte-biosciences-stock-jumps-on-positive-vitiligo-trial-data-93CH-4784014", "source_name": "Investing.com", "published_at": "2026-07-09T12:09:47", "published_display": "09 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 93, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences reports positive phase 1b vitiligo trial results", "summary": "Forte Biosciences announced positive results from its phase 1b double-blind placebo-controlled study of FB102 for vitiligo, showing a significant improvement in FVASI scores compared to placebo. The stock has seen substantial returns over the past year but is considered overvalue", "url": "https://www.investing.com/news/company-news/forte-biosciences-reports-positive-phase-1b-vitiligo-trial-results-93CH-4784004", "source_name": "Investing.com", "published_at": "2026-07-09T12:09:47", "published_display": "09 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte\u2019s skin-disease drug showed measured gains through week 24", "summary": "Forte Biosciences announced positive results from its FB102 double-blind placebo-controlled phase 1b study for vitiligo, showing statistically significant improvements in FVASI scores at week 24. The FB102-treated subjects continued to improve after the 12-week treatment period, ", "url": "https://www.stocktitan.net/news/FBRX/fb102-achieves-statistically-significant-improvement-in-vitiligo-at-z2oqz2mx9dna.html", "source_name": "Stock Titan", "published_at": "2026-07-09T12:09:47", "published_display": "09 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Forte Biosciences, Inc. Reports Material Event", "summary": "Forte Biosciences, Inc. (NASDAQ: FBRX) reported positive Phase 1b results for its drug candidate FB102 in treating vitiligo, demonstrating a statistically significant improvement in facial vitiligo area severity index (FVASI) compared to placebo. The study, involving 43 subjects,", "url": "https://www.stocktitan.net/sec-filings/FBRX/8-k-forte-biosciences-inc-reports-material-event-d53bb067243f.html", "source_name": "Stock Titan", "published_at": "2026-07-09T12:09:47", "published_display": "09 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Federated Hermes (FBRX) shows 2.11M-share, 10.31% Schedule 13G/A stake", "summary": "Federated Hermes, Inc. has filed an amended Schedule 13G/A, reporting a 2.11 million-share stake, representing 10.31% of Forte Biosciences (FBRX) common stock, as of June 30, 2026. The filing explicitly states disclaimers under Rule 13d-4, indicating that beneficial ownership of ", "url": "https://www.stocktitan.net/sec-filings/FBRX/schedule-13g-a-forte-biosciences-inc-amended-passive-investment-discl-29c3525bfd21.html", "source_name": "Stock Titan", "published_at": "2026-07-08T11:40:22", "published_display": "08 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certain Options of Forte Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 8-JUL-2026.", "summary": "Certain stock options of Forte Biosciences, Inc. (FBRX) are under a lock-up agreement that will expire on July 8, 2026. This lock-up period, which started on April 8, 2026, prevents company executive officers and directors from selling or transferring these securities without con", "url": "https://www.marketscreener.com/news/certain-options-of-forte-biosciences-inc-are-subject-to-a-lock-up-agreement-ending-on-8-jul-2026-ce7f5ed8df8af421", "source_name": "www.marketscreener.com", "published_at": "2026-07-08T00:39:08", "published_display": "08 Jul 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences Inc focuses on dermatology pipeline as investors weigh long-term prospects", "summary": "Forte Biosciences Inc (FBRX) is a clinical-stage biotechnology company developing therapies for inflammatory skin diseases, with its business model relying on advancing experimental treatments through clinical trials and regulatory approval. The company's value for investors is t", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/forte-biosciences-inc-focuses-on-dermatology-pipeline-as-investors-weigh/69716075", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T16:39:08", "published_display": "07 Jul 2026 16:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RSU vesting boosts holdings at Forte Biosciences (NASDAQ: FBRX)", "summary": "Forte Biosciences director Paul A. Wagner reported exercising 1,250 restricted stock units (RSUs) on July 1, 2026, acquiring common stock at a $0.00 conversion price. A tax-withholding transaction involved 98 shares at $21.32 each, not an open-market sale. Post-transaction, Wagne", "url": "https://www.stocktitan.net/sec-filings/FBRX/form-4-forte-biosciences-inc-insider-trading-activity-d74e047502c1.html", "source_name": "Stock Titan", "published_at": "2026-07-07T02:09:45", "published_display": "07 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FBRX - Forte Biosciences Inc Options", "summary": "This article provides a detailed financial overview of Forte Biosciences Inc (FBRX), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance metrics, insider ownership, institutional ownership, and short ", "url": "https://finviz.com/stock?t=FBRX&p=m&ty=oc&b=1&r=y5&ov=list_strike&s=10", "source_name": "Finviz", "published_at": "2026-07-04T01:09:56", "published_display": "04 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(FBRX) Movement Within Algorithmic Entry Frameworks", "summary": "This article provides an algorithmic analysis of Forte Biosciences Inc. (FBRX), highlighting strong sentiment across all horizons and a significant risk-reward setup. It outlines three institutional trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014with spe", "url": "https://news.stocktradersdaily.com/news_release/34/FBRX_Movement_Within_Algorithmic_Entry_Frameworks_070226015201_1783014721.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-02T14:12:43", "published_display": "02 Jul 2026 14:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Forte Biosciences, Inc. \u2013 NASDAQ:FBRX", "summary": "This article provides a specific financial metric, the enterprise value to EBIT forward, for Forte Biosciences, Inc. (NASDAQ: FBRX). It appears to be a stub or a section from a larger financial data platform like TradingView, given the minimal content and the surrounding navigati", "url": "https://www.tradingview.com/symbols/NASDAQ-FBRX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T19:39:14", "published_display": "30 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences, Inc.(NasdaqCM: FBRX) added to Russell 2000 Growth Benchmark", "summary": "Forte Biosciences, Inc. (NasdaqCM: FBRX) has been added to the Russell 2000 Growth Benchmark. This move highlights the company's growth trajectory and inclusion in key market indices. Forte Biosciences is a clinical-stage biopharmaceutical company focused on advancing FB102 for a", "url": "https://www.marketscreener.com/news/forte-biosciences-inc-nasdaqcm-fbrx-added-to-russell-2000-growth-benchmark-ce7f5fdede80f024", "source_name": "marketscreener.com", "published_at": "2026-06-30T00:12:43", "published_display": "30 Jun 2026 00:12", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences, Inc.(NasdaqCM:FBRX) added to Russell Small Cap Comp Growth Benchmark", "summary": "Forte Biosciences, Inc. (NasdaqCM:FBRX) has been added to the Russell Small Cap Comp Growth Benchmark. This inclusion is part of several recent additions to various Russell Growth benchmarks and indices, highlighting increased visibility for the clinical-stage biopharmaceutical c", "url": "https://www.marketscreener.com/news/forte-biosciences-inc-nasdaqcm-fbrx-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdc88f42c", "source_name": "marketscreener.com", "published_at": "2026-06-29T21:11:12", "published_display": "29 Jun 2026 21:11", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences, Inc.(NasdaqCM:FBRX) added to Russell Microcap Growth Benchmark Index", "summary": "Forte Biosciences, Inc. (NasdaqCM:FBRX) has been added to the Russell Microcap Growth Benchmark Index. The biotechnology company is focused on advancing its anti-CD122 monoclonal antibody therapeutic candidate, FB102, for broad autoimmune indications such as celiac disease and no", "url": "https://www.marketscreener.com/news/forte-biosciences-inc-nasdaqcm-fbrx-added-to-russell-microcap-growth-benchmark-index-ce7f5fded089f423", "source_name": "marketscreener.com", "published_at": "2026-06-29T08:13:00", "published_display": "29 Jun 2026 08:13", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences Inc (FBRX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "The article analyzes the financial health of Forte Biosciences Inc (FBRX), reporting a current financial score of 6.67, ranking it 230 out of 389 in the Biotechnology & Medical Research industry. It notes that the company's financial status is robust, though operating efficiency ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fbrx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-24T07:40:12", "published_display": "24 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences (FBRX) CFO receives 22,000 stock options grant", "summary": "Forte Biosciences (FBRX) Chief Financial Officer Antony A. Riley was granted 22,000 stock options with an exercise price of $17.15 per share, expiring on June 16, 2036. These compensation-related options will vest monthly over four years, starting June 16, 2026, contingent upon h", "url": "https://www.stocktitan.net/sec-filings/FBRX/form-4-forte-biosciences-inc-insider-trading-activity-ae41f028aedd.html", "source_name": "Stock Titan", "published_at": "2026-06-17T20:41:35", "published_display": "17 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences (FBRX) awards 500,000 stock options to insider Wagner", "summary": "Forte Biosciences (FBRX) has awarded 500,000 stock options to director and officer Paul A. Wagner. These options have an exercise price of $17.15 per share and expire on June 16, 2036. The award is compensation-related and vests monthly over four years, provided Wagner continues ", "url": "https://www.stocktitan.net/sec-filings/FBRX/form-4-forte-biosciences-inc-insider-trading-activity-ce616c1d28ba.html", "source_name": "Stock Titan", "published_at": "2026-06-17T20:41:35", "published_display": "17 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences Inc (FBRX) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Forte Biosciences Inc (FBRX), listing its major shareholders and institutional holdings as of recent updates. It breaks down the proportion of shares held by various investment entities and provides a historical overview of instit", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fbrx/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T15:40:37", "published_display": "17 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences Inc (FBRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "The article provides a technical analysis of Forte Biosciences Inc (FBRX), detailing its current price momentum score as 7.04 and ranking it 156 out of 388 in the Biotechnology & Medical Research industry. It identifies support at $14.38 and resistance at $21.94, suggesting suita", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fbrx/technical", "source_name": "TradingKey", "published_at": "2026-06-17T05:41:36", "published_display": "17 Jun 2026 05:41", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Forte Biosciences, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQMlNkZWhpdE8zRnlBdUJKX3I0UFcwZ0VvYUw5My1IWG5UTUZSbWFfN0dkTjYta2ZhTm5YVFJRc3dQZ0VjNmJ1Z2oxVGJEWnBfME9hbHR2UHlTX1dvVWNGNEEyWWh5Uk00aTkzNGNpMTMwRDNHS2RkOFpHVzF0aFBBMDdWdkxwYklhOWZiWUh3c0tOUnNfQzR5dVluNzFQLUwzcng4?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences Stock: Targeting Celiac Disease (NASDAQ:FBRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQdGJBRUpjcHZOaFR4Tmxfa1hOcFFvSDAwMjlIcl9QYmJMazFZRGhvWUxUOFZVZGVJTjFQMUs0U2xkOXdfdDQ4ME5iR1FDRTFZY2JtNkZtaGtWbkpwVUpKTEZZUmd1VmVuYXVqUm94NkhxcHFnZ1dKTUlrYk51MUNkRGFvMWUxMFN3akpv?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OrbiMed entities hold 5.8% of Forte Biosciences (FBRX), ownership split disclosed", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNMDlUdFJDaGNBUlBTT09SSU0tZkhmMVVKS3RmaW44dUt5ZHlyNHZwR0xVRE13X3dhcVRSZVVFWHJNLVU5RVhHSEJzYjNoZTJPa3dfZkx0RGxfWUNZajhPYzZ1ekF1Zl9IY2ljTGZSR3k0WkQxREhPZU9XYVdUb0lIYWhIMjRuSE1OdEgyWkFZSlBGNGkxc3hqU0h0TkxzZlhHMjNXMElpUnZWRVZRU1BzaC1ZOG1aWXN2Z2JQa3g3cWhsQjEzZU42dm9zMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Forte Biosciences: 2026 Is Major Inflection Point For FB102 (NASDAQ:FBRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQa0NRcVJLRHhqN3o3YTNwb0hsLWVScVlqazNvc3VsT21iQnQ0OGJHWkRmOXZ3Q19KRWxwRkwxc2NwRExzMVZXalZNNWZuMmlQNUpmLWxCTTNHV2ZCX2tIcXZ6TGJ2bVBkMEs1Ri15VHQ4dGFEMUdIaVpkY25xOVJERGwwWXlDeXBBNlZyUzFhbzNOOFBfSkduRV8xR2U?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Should I buy Forte Biosciences (FBRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE5Wd3hrWmZobjk4blFzX0dXUWFpMERqaWUycUczUE8tbGlMWmthLUJyVmdFUU9LMUM2eEx6SkhfVjFSUkgxSnlEdXRTUWR3eHNTVXJQelhEN3hpTEVaT0ZCWjJyUFpDMGk2ZmE3Tg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Very Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-11T08:00:00+00:00", "published_display": "11 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences Public Offering: 4 Major Banks Lead Autoimmune Drug Developer's Stock Sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNd1BGUXBCbmR4c2d6YUhISXdfUDVfeHpoNWs0MDNYVWpIX0s2NUUxeDV6YnBlSTVZNE9uY2NYUG1DNENfVzlyWXVmZzZkQU5Bc18xbVZiZVR2aU9LSlgwTVpuXzloSHczc2w5djRLV2dqTWxPcDRmZEl2alZFMnNQZTZTM1RCQU9YUG9ueGRGOFFEVERRSXM4Zll4SjhDQkE?oc=5", "source_name": "Stock Titan", "published_at": "2025-06-24T07:00:00+00:00", "published_display": "24 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Forte Biosciences stock hits 52-week high at $45.39", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOYURjY3NCbGx3RzhJTG1nUFJOcFM2aFk3dHgzZ2N1bzZmLWVrYUduOXdFbFZNY3d4eVhJUUNlcDJBLWoxZFdjYzdsbjFjbHVBN01pZzVMQ2lFZjRnX3dTaE9tSldnZkRGQngwcERYWHJmQm5MMUNiZHlwZ2xpcDFPeUlfMjlPaTVvOGtwWW12TXgxS0dmeGF5Z3pZS2VOYTQ4T0Y3WVVmRWs?oc=5", "source_name": "Investing.com", "published_at": "2026-07-15T14:19:45+00:00", "published_display": "15 Jul 2026 14:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences stock hits 52-week high at $45.39 By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPT3R4RW90VUF0QS1UMkxmTzR6eUlQRmFveE5wZ29JX3VpdUtSdnNqS0VERnpuNmtSZC1pa2ZlejhtVTItYl9sLU9QR3hhNFVQYzZGT0pJa1B4RTFZTi1oOTI3aUN4YkVOSGZweUdPZHgyMlhSYmlkY1JETWpGWHhIX0pxTEFFQWVTTFpmMUhiMG9WckJ0TVlXNUxXc1ZDU0FkREN5UjJrWHctYjFZVGc?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-15T14:18:46+00:00", "published_display": "15 Jul 2026 14:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FEDERATED HERMES, INC. Acquires Additional Shares in Forte Biosciences Inc", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOQnZTdXhtbU1ENkcyQjNYcUxiLU5XSmpOLUV2ZExjbUs0OVdyX0haNFpNS1o2S2xXeHNSYVFtWmZld1NpdnFTOVU0TVNaQnFRNncxUmdjVWxhNHBLYi1jdVA2OWp1aUgtRWs2dW9TaTBUSXF3emdSVEZoQTZrNU1DUlN0VlhyMV9KWUx3M28xQlg4aG1nLW5IaTd0M2o5U2hfUHk0cEVFNHNvN1E2d29QdQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-15T01:05:22+00:00", "published_display": "15 Jul 2026 01:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences, Inc. (FBRX) Discusses Positive Results From FB102 Phase 1b Vitiligo Study and Mechanism of Action - Slideshow (NASDAQ:FBRX) 2026-07-13", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxOSGZ6S2lRMU85NzE4RFVqM3RoYVNQR0toZTU2QkVETHZBVmFPZ0I2RFpBWGFiYi16cWRnSVUzbWFOcTlKbGNuTy1NVVF4WTN6RTEzTG9TWmc2NzdlRVhfTHd1SUtzUnRjWF9LVFppenl4eDVNT052WV96ekVvcDl5ZzNuYTZiNThiVkgzNWF4NmZSeWhhckgtTnJCNGpfMmpTR3RwYXFCWDFhMXhFQkJoY3BtS0FWTFpqSkdRZzNGbWRudVF5dmxaUnhxVE1fdw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-13T23:06:40+00:00", "published_display": "13 Jul 2026 23:06", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Forte Biosciences, Inc. \u2013 NASDAQ:FBRX", "summary": "The article focuses on the \"Price to book forward\" financial metric for Forte Biosciences, Inc. (NASDAQ: FBRX). It is presented as part of TradingView's financial data offerings for the biotechnology company. The content appears to be a stub or a section within a larger financial", "url": "https://www.tradingview.com/symbols/NASDAQ-FBRX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T20:13:40", "published_display": "13 Jul 2026 20:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gJBVV95cUxQaFBiT0hkUnd5SGMwZXNLMF83TmU4aFlYOHRsWUd6RWQ4eWJLSjQ2TURfYTNYVWF1R01hajN4T0tKSUg1bVRPSW43NXdQX0Z3SXRVSGlqODlwTlRqcGZtMlVEeUcwLTVoRmJfQmxJdERoOXdxVFJreWp3dmN4djhmLTJUYzdPRWxWem9zeTFxWWZVd0hMdmhCdkkzQjJ0QTU5RFkybUdKQ2EtUHROQzFJYlFWa3NGZkVtX1NZMDQ3bjVkdkpZTGZfNzFSZk5UZGxYNmFncHpXMGlYZ2x0RkI1di1lUmZjcGhIZ3NGbEVZTVBuMzZTdFlQLVhkMTdCZGpocjItRE5nYmQ3V1BLdnVtQ2cwbjJfd19aMl9aM0F2eDltTVRqczBabm1Sbk1hTy1RTk9OYjI3NlpLenRLLWYxVXlGT0JGZHRES2xCaEkwTml2Zw?oc=5", "source_name": "Moomoo", "published_at": "2026-07-13T14:44:45+00:00", "published_display": "13 Jul 2026 14:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Forte Biosciences Inc. \u2013 FWB:37T", "summary": "This article provides the enterprise value to revenue forward for Forte Biosciences Inc., traded on the Frankfurt Stock Exchange under the symbol FWB:37T. It highlights the financial data available for the company, indicating the market is currently closed with no trades. The con", "url": "https://www.tradingview.com/symbols/FWB-37T/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T10:10:39", "published_display": "13 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FBRX Stock Soars As FB102 Vitiligo Data Ignite Biotech Momentum", "summary": "Forte Biosciences Inc. (FBRX) stock surged by 13.65% after announcing positive Phase 1b clinical trial data for its FB102 vitiligo treatment, showing significant facial vitiligo improvements, durable off-drug benefits, and a clean safety profile. This strong data has increased in", "url": "https://stockstotrade.com/news/forte-biosciences-inc-fbrx-news-2026_07_10/", "source_name": "StocksToTrade", "published_at": "2026-07-10T16:20:54", "published_display": "10 Jul 2026 16:20", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences' Vitiligo Triumph: A High-Stakes Bet on Broad Autoimmune Potential", "summary": "Forte Biosciences' stock surged after positive Phase 1b clinical trial results for its drug candidate, FB102, in vitiligo patients. The study showed statistically significant improvements in vitiligo symptoms with a favorable safety profile and sustained efficacy post-treatment. ", "url": "https://www.kavout.com/market-lens/forte-biosciences-vitiligo-triumph-a-high-stakes-bet-on-broad-autoimmune-potential", "source_name": "Kavout | AI", "published_at": "2026-07-10T16:09:48", "published_display": "10 Jul 2026 16:09", "sentiment": "positive", "sentiment_pct": 85, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data", "summary": "Forte Biosciences (FBRX) shares surged 78.3% following positive top-line results from a phase Ib study of FB102 for vitiligo. The study showed statistically significant improvements in facial depigmentation and a favorable safety profile for FB102, boosting investor confidence. T", "url": "https://www.tradingview.com/news/zacks:9ae15f344094b:0-fbrx-stock-rallies-78-on-positive-early-stage-vitiligo-study-data/", "source_name": "TradingView", "published_at": "2026-07-10T15:39:57", "published_display": "10 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 85, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences Skin Pigmentation Disorder Drug Shows Strong Efficacy, Safety In Early Study", "summary": "Forte Biosciences' FB102 drug showed significant efficacy and a favorable safety profile in an early-stage study for vitiligo, a skin pigmentation disorder. The Phase 1b trial demonstrated statistically significant improvements in facial repigmentation, with benefits continuing e", "url": "https://www.sahmcapital.com/news/content/forte-biosciences-skin-pigmentation-disorder-drug-shows-strong-efficacy-safety-in-early-study-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T15:09:48", "published_display": "10 Jul 2026 15:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences' FB102 Hits Key Goal in Vitiligo Study, Shows Durable Improvement", "summary": "Forte Biosciences announced that its drug FB102 met its primary endpoint in a small, placebo-controlled vitiligo study, demonstrating a statistically significant and durable improvement in facial Vitiligo Area Scoring Index. The study showed continued improvement in patients even", "url": "https://finance.yahoo.com/healthcare/articles/forte-biosciences-fb102-hits-key-140238343.html", "source_name": "Market source", "published_at": "2026-07-10T14:09:24", "published_display": "10 Jul 2026 14:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences: FB102 Is Becoming A Platform Story, Not A Single-Indication Bet (NASDAQ:FBRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPek5fdVdDZ2pTWm9RTHpOS3dXcnR3bzJpeHMwNlAyRUd4OGVqQ2JGaEVSREhDYnhWTDdhcW54QU9TTjE3aE5aVUxhc3IzeUxQRGVya3p3bVhyejUyeHJ5VGFjQ1pFMnFZd2hPSmFqMTQ2OTI1QXlMNTJxVHFuQ3dmdWpJb3hxQ2RHRlFPNk05RldVSlA0UG9jOWQ3QXZySTZydTFiZUhXYkttV3o3dFAzbTZQZnJSU3FGQzVNQXhR?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-10T12:25:00+00:00", "published_display": "10 Jul 2026 12:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$Forte Biosciences (FBRX.US)$ Why $FBRX surged today", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNXzNkLWpQX1g4WU1wTE9FQ1JwNFduSnAwVlUtOFhVWS1FWUpOUUNQR3JxTEE2dGo2MkdmNjE3VUNRaE4tcUpPQjNRZGNiVGJ2NnlTaGJRVGVPNU1fcU84UG41WkphaEU5dzZfV21xTUVYWUFwakkwSmdFR0o0bERwOVhxUTFFdkRidnRfU2ZwbHI3UndfS0F2TXBYMjc4WDVtUTVuVS1BWmpkbE9KcXlhTWVB?oc=5", "source_name": "Moomoo", "published_at": "2026-07-10T02:48:22+00:00", "published_display": "10 Jul 2026 02:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Bio surges on early-stage trial data for vitiligo therapy", "summary": "Forte Biosciences' stock surged after the company released early-stage trial data for its lead asset, FB102, a vitiligo therapy. The results showed a statistically significant improvement in vitiligo symptoms as early as nine weeks, leading to a positive market reaction for FBRX.", "url": "https://seekingalpha.com/news/4612692-forte-bio-surges-trial-data-vitiligo-drug", "source_name": "Seeking Alpha", "published_at": "2026-07-10T03:11:25", "published_display": "10 Jul 2026 03:11", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences shares surge after positive phase 1b vitiligo results", "summary": "", "url": "https://finance.yahoo.com/m/6ff17908-f387-3589-adf4-3cc866f6d614/forte-biosciences-shares.html", "source_name": "Proactive", "published_at": "2026-07-09T17:26:00+00:00", "published_display": "09 Jul 2026 17:26", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences Reports Positive Phase 1b Vitiligo Results", "summary": "Forte Biosciences reported positive results from its Phase 1b trial of FB102 for vitiligo, showing a significant mean improvement in facial vitiligo and a favorable safety profile. These findings support the potential of FB102 and the company's broader autoimmune pipeline, includ", "url": "https://www.tipranks.com/news/company-announcements/forte-biosciences-reports-positive-phase-1b-vitiligo-results", "source_name": "TipRanks", "published_at": "2026-07-09T14:41:15", "published_display": "09 Jul 2026 14:41", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences reports positive Phase 1b vitiligo data for FB102 with 29.6% mean FVASI improvement", "summary": "Forte Biosciences", "url": "https://www.tradingview.com/news/tradingview:79e94f7b74bb8:0-forte-biosciences-reports-positive-phase-1b-vitiligo-data-for-fb102-with-29-6-mean-fvasi-improvement/", "source_name": "TradingView", "published_at": "2026-07-09T14:41:15", "published_display": "09 Jul 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences Shares Climb After Positive Phase 1b Vitiligo Trial Results (FBRX)", "summary": "Forte Biosciences (NASDAQ:FBRX) shares rose 12% following positive results from its Phase 1b trial of FB102 for vitiligo. The study demonstrated statistically significant improvements in facial repigmentation, particularly in patients with more extensive disease, and showcased a ", "url": "https://finance.yahoo.com/healthcare/articles/forte-biosciences-shares-climb-positive-140925067.html", "source_name": "Market source", "published_at": "2026-07-09T14:09:47", "published_display": "09 Jul 2026 14:09", "sentiment": "positive", "sentiment_pct": 94, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enovix, Forte Biosciences rally premarket; PepsiCo slips", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNTGhlU0FPQXN5NHl3NTBRSkFwMElRcEdvZy1CSi1HT3dkMTNXdTY4SUFHcUxGOXprcGpuSHBMa01oQWtfbC1RbFZwc0ZhMU1lNFl6bWRhaXNjR25waWI1Ykc0UmdfeFNMYWxWRnl1ckF0NlN3eF8wNklTTk14UWI3SUtNUndwckpHSnZ0YWEtMG1HZU92NzNnLVFaWWgxQUtwLXA1MGlBUVRUem5yU1pSOQ?oc=5", "source_name": "Investing.com", "published_at": "2026-07-09T12:34:05+00:00", "published_display": "09 Jul 2026 12:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences stock jumps on positive vitiligo trial data", "summary": "Forte Biosciences (NASDAQ:FBRX) shares surged 12% after announcing positive results from its phase 1b study of FB102 for vitiligo. The treatment showed statistically significant improvement in FVASI from baseline, with 29.6% for FB102 compared to 7.9% for placebo, and even greate", "url": "https://www.investing.com/news/stock-market-news/forte-biosciences-stock-jumps-on-positive-vitiligo-trial-data-93CH-4784014", "source_name": "Investing.com", "published_at": "2026-07-09T12:09:47", "published_display": "09 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 93, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences reports positive phase 1b vitiligo trial results", "summary": "Forte Biosciences announced positive results from its phase 1b double-blind placebo-controlled study of FB102 for vitiligo, showing a significant improvement in FVASI scores compared to placebo. The stock has seen substantial returns over the past year but is considered overvalue", "url": "https://www.investing.com/news/company-news/forte-biosciences-reports-positive-phase-1b-vitiligo-trial-results-93CH-4784004", "source_name": "Investing.com", "published_at": "2026-07-09T12:09:47", "published_display": "09 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte\u2019s skin-disease drug showed measured gains through week 24", "summary": "Forte Biosciences announced positive results from its FB102 double-blind placebo-controlled phase 1b study for vitiligo, showing statistically significant improvements in FVASI scores at week 24. The FB102-treated subjects continued to improve after the 12-week treatment period, ", "url": "https://www.stocktitan.net/news/FBRX/fb102-achieves-statistically-significant-improvement-in-vitiligo-at-z2oqz2mx9dna.html", "source_name": "Stock Titan", "published_at": "2026-07-09T12:09:47", "published_display": "09 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Forte Biosciences, Inc. Reports Material Event", "summary": "Forte Biosciences, Inc. (NASDAQ: FBRX) reported positive Phase 1b results for its drug candidate FB102 in treating vitiligo, demonstrating a statistically significant improvement in facial vitiligo area severity index (FVASI) compared to placebo. The study, involving 43 subjects,", "url": "https://www.stocktitan.net/sec-filings/FBRX/8-k-forte-biosciences-inc-reports-material-event-d53bb067243f.html", "source_name": "Stock Titan", "published_at": "2026-07-09T12:09:47", "published_display": "09 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Federated Hermes (FBRX) shows 2.11M-share, 10.31% Schedule 13G/A stake", "summary": "Federated Hermes, Inc. has filed an amended Schedule 13G/A, reporting a 2.11 million-share stake, representing 10.31% of Forte Biosciences (FBRX) common stock, as of June 30, 2026. The filing explicitly states disclaimers under Rule 13d-4, indicating that beneficial ownership of ", "url": "https://www.stocktitan.net/sec-filings/FBRX/schedule-13g-a-forte-biosciences-inc-amended-passive-investment-discl-29c3525bfd21.html", "source_name": "Stock Titan", "published_at": "2026-07-08T11:40:22", "published_display": "08 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Certain Options of Forte Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 8-JUL-2026.", "summary": "Certain stock options of Forte Biosciences, Inc. (FBRX) are under a lock-up agreement that will expire on July 8, 2026. This lock-up period, which started on April 8, 2026, prevents company executive officers and directors from selling or transferring these securities without con", "url": "https://www.marketscreener.com/news/certain-options-of-forte-biosciences-inc-are-subject-to-a-lock-up-agreement-ending-on-8-jul-2026-ce7f5ed8df8af421", "source_name": "www.marketscreener.com", "published_at": "2026-07-08T00:39:08", "published_display": "08 Jul 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences Inc focuses on dermatology pipeline as investors weigh long-term prospects", "summary": "Forte Biosciences Inc (FBRX) is a clinical-stage biotechnology company developing therapies for inflammatory skin diseases, with its business model relying on advancing experimental treatments through clinical trials and regulatory approval. The company's value for investors is t", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/forte-biosciences-inc-focuses-on-dermatology-pipeline-as-investors-weigh/69716075", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T16:39:08", "published_display": "07 Jul 2026 16:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RSU vesting boosts holdings at Forte Biosciences (NASDAQ: FBRX)", "summary": "Forte Biosciences director Paul A. Wagner reported exercising 1,250 restricted stock units (RSUs) on July 1, 2026, acquiring common stock at a $0.00 conversion price. A tax-withholding transaction involved 98 shares at $21.32 each, not an open-market sale. Post-transaction, Wagne", "url": "https://www.stocktitan.net/sec-filings/FBRX/form-4-forte-biosciences-inc-insider-trading-activity-d74e047502c1.html", "source_name": "Stock Titan", "published_at": "2026-07-07T02:09:45", "published_display": "07 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FBRX - Forte Biosciences Inc Options", "summary": "This article provides a detailed financial overview of Forte Biosciences Inc (FBRX), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance metrics, insider ownership, institutional ownership, and short ", "url": "https://finviz.com/stock?t=FBRX&p=m&ty=oc&b=1&r=y5&ov=list_strike&s=10", "source_name": "Finviz", "published_at": "2026-07-04T01:09:56", "published_display": "04 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(FBRX) Movement Within Algorithmic Entry Frameworks", "summary": "This article provides an algorithmic analysis of Forte Biosciences Inc. (FBRX), highlighting strong sentiment across all horizons and a significant risk-reward setup. It outlines three institutional trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014with spe", "url": "https://news.stocktradersdaily.com/news_release/34/FBRX_Movement_Within_Algorithmic_Entry_Frameworks_070226015201_1783014721.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-02T14:12:43", "published_display": "02 Jul 2026 14:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Forte Biosciences, Inc. \u2013 NASDAQ:FBRX", "summary": "This article provides a specific financial metric, the enterprise value to EBIT forward, for Forte Biosciences, Inc. (NASDAQ: FBRX). It appears to be a stub or a section from a larger financial data platform like TradingView, given the minimal content and the surrounding navigati", "url": "https://www.tradingview.com/symbols/NASDAQ-FBRX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T19:39:14", "published_display": "30 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences, Inc.(NasdaqCM: FBRX) added to Russell 2000 Growth Benchmark", "summary": "Forte Biosciences, Inc. (NasdaqCM: FBRX) has been added to the Russell 2000 Growth Benchmark. This move highlights the company's growth trajectory and inclusion in key market indices. Forte Biosciences is a clinical-stage biopharmaceutical company focused on advancing FB102 for a", "url": "https://www.marketscreener.com/news/forte-biosciences-inc-nasdaqcm-fbrx-added-to-russell-2000-growth-benchmark-ce7f5fdede80f024", "source_name": "marketscreener.com", "published_at": "2026-06-30T00:12:43", "published_display": "30 Jun 2026 00:12", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences, Inc.(NasdaqCM:FBRX) added to Russell Small Cap Comp Growth Benchmark", "summary": "Forte Biosciences, Inc. (NasdaqCM:FBRX) has been added to the Russell Small Cap Comp Growth Benchmark. This inclusion is part of several recent additions to various Russell Growth benchmarks and indices, highlighting increased visibility for the clinical-stage biopharmaceutical c", "url": "https://www.marketscreener.com/news/forte-biosciences-inc-nasdaqcm-fbrx-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdc88f42c", "source_name": "marketscreener.com", "published_at": "2026-06-29T21:11:12", "published_display": "29 Jun 2026 21:11", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences, Inc.(NasdaqCM:FBRX) added to Russell Microcap Growth Benchmark Index", "summary": "Forte Biosciences, Inc. (NasdaqCM:FBRX) has been added to the Russell Microcap Growth Benchmark Index. The biotechnology company is focused on advancing its anti-CD122 monoclonal antibody therapeutic candidate, FB102, for broad autoimmune indications such as celiac disease and no", "url": "https://www.marketscreener.com/news/forte-biosciences-inc-nasdaqcm-fbrx-added-to-russell-microcap-growth-benchmark-index-ce7f5fded089f423", "source_name": "marketscreener.com", "published_at": "2026-06-29T08:13:00", "published_display": "29 Jun 2026 08:13", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences Inc (FBRX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "The article analyzes the financial health of Forte Biosciences Inc (FBRX), reporting a current financial score of 6.67, ranking it 230 out of 389 in the Biotechnology & Medical Research industry. It notes that the company's financial status is robust, though operating efficiency ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fbrx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-24T07:40:12", "published_display": "24 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences (FBRX) CFO receives 22,000 stock options grant", "summary": "Forte Biosciences (FBRX) Chief Financial Officer Antony A. Riley was granted 22,000 stock options with an exercise price of $17.15 per share, expiring on June 16, 2036. These compensation-related options will vest monthly over four years, starting June 16, 2026, contingent upon h", "url": "https://www.stocktitan.net/sec-filings/FBRX/form-4-forte-biosciences-inc-insider-trading-activity-ae41f028aedd.html", "source_name": "Stock Titan", "published_at": "2026-06-17T20:41:35", "published_display": "17 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences (FBRX) awards 500,000 stock options to insider Wagner", "summary": "Forte Biosciences (FBRX) has awarded 500,000 stock options to director and officer Paul A. Wagner. These options have an exercise price of $17.15 per share and expire on June 16, 2036. The award is compensation-related and vests monthly over four years, provided Wagner continues ", "url": "https://www.stocktitan.net/sec-filings/FBRX/form-4-forte-biosciences-inc-insider-trading-activity-ce616c1d28ba.html", "source_name": "Stock Titan", "published_at": "2026-06-17T20:41:35", "published_display": "17 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences Inc (FBRX) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Forte Biosciences Inc (FBRX), listing its major shareholders and institutional holdings as of recent updates. It breaks down the proportion of shares held by various investment entities and provides a historical overview of instit", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fbrx/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T15:40:37", "published_display": "17 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences Inc (FBRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "The article provides a technical analysis of Forte Biosciences Inc (FBRX), detailing its current price momentum score as 7.04 and ranking it 156 out of 388 in the Biotechnology & Medical Research industry. It identifies support at $14.38 and resistance at $21.94, suggesting suita", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fbrx/technical", "source_name": "TradingKey", "published_at": "2026-06-17T05:41:36", "published_display": "17 Jun 2026 05:41", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Forte Biosciences, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQMlNkZWhpdE8zRnlBdUJKX3I0UFcwZ0VvYUw5My1IWG5UTUZSbWFfN0dkTjYta2ZhTm5YVFJRc3dQZ0VjNmJ1Z2oxVGJEWnBfME9hbHR2UHlTX1dvVWNGNEEyWWh5Uk00aTkzNGNpMTMwRDNHS2RkOFpHVzF0aFBBMDdWdkxwYklhOWZiWUh3c0tOUnNfQzR5dVluNzFQLUwzcng4?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences Stock: Targeting Celiac Disease (NASDAQ:FBRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQdGJBRUpjcHZOaFR4Tmxfa1hOcFFvSDAwMjlIcl9QYmJMazFZRGhvWUxUOFZVZGVJTjFQMUs0U2xkOXdfdDQ4ME5iR1FDRTFZY2JtNkZtaGtWbkpwVUpKTEZZUmd1VmVuYXVqUm94NkhxcHFnZ1dKTUlrYk51MUNkRGFvMWUxMFN3akpv?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OrbiMed entities hold 5.8% of Forte Biosciences (FBRX), ownership split disclosed", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNMDlUdFJDaGNBUlBTT09SSU0tZkhmMVVKS3RmaW44dUt5ZHlyNHZwR0xVRE13X3dhcVRSZVVFWHJNLVU5RVhHSEJzYjNoZTJPa3dfZkx0RGxfWUNZajhPYzZ1ekF1Zl9IY2ljTGZSR3k0WkQxREhPZU9XYVdUb0lIYWhIMjRuSE1OdEgyWkFZSlBGNGkxc3hqU0h0TkxzZlhHMjNXMElpUnZWRVZRU1BzaC1ZOG1aWXN2Z2JQa3g3cWhsQjEzZU42dm9zMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences: 2026 Is Major Inflection Point For FB102 (NASDAQ:FBRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQa0NRcVJLRHhqN3o3YTNwb0hsLWVScVlqazNvc3VsT21iQnQ0OGJHWkRmOXZ3Q19KRWxwRkwxc2NwRExzMVZXalZNNWZuMmlQNUpmLWxCTTNHV2ZCX2tIcXZ6TGJ2bVBkMEs1Ri15VHQ4dGFEMUdIaVpkY25xOVJERGwwWXlDeXBBNlZyUzFhbzNOOFBfSkduRV8xR2U?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Forte Biosciences (FBRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE5Wd3hrWmZobjk4blFzX0dXUWFpMERqaWUycUczUE8tbGlMWmthLUJyVmdFUU9LMUM2eEx6SkhfVjFSUkgxSnlEdXRTUWR3eHNTVXJQelhEN3hpTEVaT0ZCWjJyUFpDMGk2ZmE3Tg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Not Very Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-11T08:00:00+00:00", "published_display": "11 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Forte Biosciences Public Offering: 4 Major Banks Lead Autoimmune Drug Developer's Stock Sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNd1BGUXBCbmR4c2d6YUhISXdfUDVfeHpoNWs0MDNYVWpIX0s2NUUxeDV6YnBlSTVZNE9uY2NYUG1DNENfVzlyWXVmZzZkQU5Bc18xbVZiZVR2aU9LSlgwTVpuXzloSHczc2w5djRLV2dqTWxPcDRmZEl2alZFMnNQZTZTM1RCQU9YUG9ueGRGOFFEVERRSXM4Zll4SjhDQkE?oc=5", "source_name": "Stock Titan", "published_at": "2025-06-24T07:00:00+00:00", "published_display": "24 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 54, "sentiment_summary": {"positive": 21, "negative": 2, "neutral": 31, "score": 61, "total": 54, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 18.45, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 10.6, "count": 20}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 21, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 43.92, "latest_week": "2026-07-10", "one_week_move": 109.9, "four_week_move": 150.1, "twelve_week_move": 29.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.409143, "market_dynamics_buy_signal": false, "relative_strength": 80.06952, "fair_value_gap": 168.9, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 47.3761, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+109.9% over one week, +150.1% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 72, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 9}, {"label": "Market source", "count": 7}, {"label": "TradingView", "count": 6}, {"label": "Seeking Alpha", "count": 5}, {"label": "Investing.com", "count": 4}, {"label": "marketscreener.com", "count": 3}, {"label": "TradingKey", "count": 3}, {"label": "simplywall.st", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 20}, {"label": "Deals and strategy", "count": 1}, {"label": "Regulatory and legal", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "61/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "6", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+109.9% over one week, +150.1% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Forte Biosciences stock hits 52-week high at $45.39"}], "updated_at": "2026-07-16T03:30:11.754532+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}